Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH (LASERLESS)

Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (LASER LESS TRIAL)

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Study Overview

• Status: Unknown
• Conditions: Proliferative Diabetic Retinopathy
• Intervention / Treatment: Drug: Aflibercept; Procedure: Endolaserless Vitrectomy

Detailed Description

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Augusta, Georgia, United States, 30809
      • Recruiting
      • Southeast Retina Center, PC
      • Contact: Siobhan Ortiz; Phone Number: 706-650-0061

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adults age >18 years with Diabetes Mellitus
2. PDR- related vitreous hemorrhage and not of another cause
3. BCVA Vision LP or better
4. Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage
5. Willing and able to comply with clinic visits and study-related procedures
6. Provide HIPPA and signed informed consent prior to any study procedures

Exclusion Criteria:

1. A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.)
2. Participation in an investigational trial within 30 days of enrollment
3. Known allergy to IAI
4. Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment
5. For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years
6. History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye
7. History of vitrectomy in the study eye
8. History or evidence for rhegmatogenous retinal detachment in the study eye
9. Evidence of traction retinal detachment involving or threatening central macula in the study eye
10. Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc)
11. Intravitreal anti-VEGF injection in the study eye <4weeks from enrollment.
12. Pregnant or breast-feeding women
13. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: IAI q8 week Group; Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group ("q8 week Group") where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment	Drug: Aflibercept; . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.; Other Names: Eylea; 2 mg/0.05 mL single use vial for intravitreal injection; Procedure: Endolaserless Vitrectomy; Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
ACTIVE_COMPARATOR: IAI q16 week Group; Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.	Drug: Aflibercept; . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.; Other Names: Eylea; 2 mg/0.05 mL single use vial for intravitreal injection; Procedure: Endolaserless Vitrectomy; Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:	Examples include worsened acuity >30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52.	Through 52 weeks from Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change in BCVA letter score	Mean change in BCVA letter score over time through week 52	52 weeks from Baseline
Mean BCVA letter score	Mean BCVA letter score over time through week 52	52 weeks from Baseline
Proportion of eyes with progression of PDR	Proportion of eyes with progression of PDR as defined above at any time point through week 52	Through 52 weeks from Baseline
Mean OCT CSF thickness	Mean OCT CSF thickness over time through week 52	Through 52 weeks from Baseline
Proportion of eyes with OCT CSF thickness <300um	Proportion of eyes with OCT CSF thickness <300um at week 52	Through 52 weeks from Baseline
Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage	Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52	Through 52 weeks from Baseline
Proportion of eyes with absence of active neovascularization	Proportion of eyes with absence of active neovascularization by Optos widefield fluorescein angiography at week 52	Through 52 weeks from Baseline
Proportion of eyes with absence of active neovascularization	Proportion of eyes with absence of active neovascularization by 7 standard field photography at week 52	Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage	Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline angiograms at week 52	Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization	Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization from baseline angiograms at week 52	Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance	Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline photographs at week 52	Through 52 weeks from Baseline
Mean cumulative score and change for the combined 30-2 and 60-4 HVF test	Mean cumulative score and change for the combined 30-2 and 60-4 HVF test from week 4 to week 52.	Through 52 weeks from Baseline
Proportion of eyes requiring additional IAI other than mandatory injections	Proportion of eyes requiring additional IAI other than mandatory injections through week 52	Through 52 weeks from Baseline
Proportion of eye with progression of PDR requiring rescue PRP standard of care	Proportion of eye with progression of PDR requiring rescue PRP standard of care at any time point through 52 weeks	Through 52 weeks from Baseline
Proportion of eyes requiring PRP or retinopexy	Proportion of eyes requiring PRP or retinopexy through week 52	Through 52 weeks from Baseline
Proportion of eyes requiring additional vitrectomy	Proportion of eyes requiring additional vitrectomy through week 52	Through 52 weeks from Baseline
Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy	Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy	Through 52 weeks from Baseline

Collaborators and Investigators

• Sponsor: Southeast Retina Center, Georgia
• Investigators: Principal Investigator: Dennis M Marcus, MD, Southeast Retina Center, PC

Study record dates

Study Major Dates

• Study Start: June 1, 2016
• Primary Completion (ANTICIPATED): June 1, 2018
• Study Completion (ANTICIPATED): June 1, 2018

Study Registration Dates

• First Submitted: November 4, 2015
• First Submitted That Met QC Criteria: November 23, 2016
• First Posted (ESTIMATE): November 29, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): November 29, 2016
• Last Update Submitted That Met QC Criteria: November 23, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Proliferative Diabetic Retinopathy; Aflibercept; Vitreous Hemorrhage
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Eye Diseases; Endocrine System Diseases; Diabetic Angiopathies; Diabetes Complications; Diabetes Mellitus; Hemorrhage; Eye Hemorrhage; Retinal Diseases; Diabetic Retinopathy; Vitreous Hemorrhage; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Aflibercept
• Other Study ID Numbers: VGFTe-DR-1548

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED